Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 21543616)


Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration.

Sleiman SF, Langley BC, Basso M, Berlin J, Xia L, Payappilly JB, Kharel MK, Guo H, Marsh JL, Thompson LM, Mahishi L, Ahuja P, MacLellan WR, Geschwind DH, Coppola G, Rohr J, Ratan RR.

J Neurosci. 2011 May 4;31(18):6858-70. doi: 10.1523/JNEUROSCI.0710-11.2011. Erratum in: J Neurosci. 2012 May 9;32(19):6743.


Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons.

Ryu H, Lee J, Zaman K, Kubilis J, Ferrante RJ, Ross BD, Neve R, Ratan RR.

J Neurosci. 2003 May 1;23(9):3597-606.


Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts.

Previdi S, Malek A, Albertini V, Riva C, Capella C, Broggini M, Carbone GM, Rohr J, Catapano CV.

Gynecol Oncol. 2010 Aug 1;118(2):182-8. doi: 10.1016/j.ygyno.2010.03.020. Epub 2010 May 8.


Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease.

Ferrante RJ, Ryu H, Kubilus JK, D'Mello S, Sugars KL, Lee J, Lu P, Smith K, Browne S, Beal MF, Kristal BS, Stavrovskaya IG, Hewett S, Rubinsztein DC, Langley B, Ratan RR.

J Neurosci. 2004 Nov 17;24(46):10335-42.


Estrogen regulated expression of the p21 Waf1/Cip1 gene in estrogen receptor positive human breast cancer cells.

Mandal S, Davie JR.

J Cell Physiol. 2010 Jul;224(1):28-32. doi: 10.1002/jcp.22078.


Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target.

Remsing LL, Bahadori HR, Carbone GM, McGuffie EM, Catapano CV, Rohr J.

Biochemistry. 2003 Jul 15;42(27):8313-24.


Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin.

Petrovic V, Costa RH, Lau LF, Raychaudhuri P, Tyner AL.

Cancer Biol Ther. 2010 Jun 15;9(12):1008-16. Epub 2010 Jun 6.


Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection.

Langley B, D'Annibale MA, Suh K, Ayoub I, Tolhurst A, Bastan B, Yang L, Ko B, Fisher M, Cho S, Beal MF, Ratan RR.

J Neurosci. 2008 Jan 2;28(1):163-76. doi: 10.1523/JNEUROSCI.3200-07.2008.


Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites.

Lee TJ, Jung EM, Lee JT, Kim S, Park JW, Choi KS, Kwon TK.

Mol Cancer Ther. 2006 Nov;5(11):2737-46.


Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.

Jia Z, Gao Y, Wang L, Li Q, Zhang J, Le X, Wei D, Yao JC, Chang DZ, Huang S, Xie K.

Cancer Res. 2010 Feb 1;70(3):1111-9. doi: 10.1158/0008-5472.CAN-09-3282. Epub 2010 Jan 19.


Inhibition of p53-mediated transcriptional responses by mithramycin A.

Koutsodontis G, Kardassis D.

Oncogene. 2004 Dec 9;23(57):9190-200.


Sp1 coordinately regulates de novo lipogenesis and proliferation in cancer cells.

Lu S, Archer MC.

Int J Cancer. 2010 Jan 15;126(2):416-25. doi: 10.1002/ijc.24761.


Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway.

Ryu H, Lee J, Olofsson BA, Mwidau A, Dedeoglu A, Escudero M, Flemington E, Azizkhan-Clifford J, Ferrante RJ, Ratan RR.

Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4281-6. Epub 2003 Mar 14. Erratum in: Proc Natl Acad Sci U S A. 2003 May 27;100(11):6890. Deodoglu, A [corrected to Dedeoglu, A].


Sp1 and Sp3 transcription factors upregulate the proximal promoter of the human prostate-specific antigen gene in prostate cancer cells.

Shin T, Sumiyoshi H, Matsuo N, Satoh F, Nomura Y, Mimata H, Yoshioka H.

Arch Biochem Biophys. 2005 Mar 15;435(2):291-302.


Mithramycin, an agent for developing new therapeutic drugs for neurodegenerative diseases.

Osada N, Kosuge Y, Ishige K, Ito Y.

J Pharmacol Sci. 2013;122(4):251-6. Epub 2013 Jul 30. Review.


Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer.

Malek A, Núñez LE, Magistri M, Brambilla L, Jovic S, Carbone GM, Morís F, Catapano CV.

PLoS One. 2012;7(4):e35130. doi: 10.1371/journal.pone.0035130. Epub 2012 Apr 19.


Low-dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin-3 in gynecologic cancers.

Ohgami T, Kato K, Kobayashi H, Sonoda K, Inoue T, Yamaguchi S, Yoneda T, Wake N.

Cancer Sci. 2010 Jun;101(6):1387-95. doi: 10.1111/j.1349-7006.2010.01543.x. Epub 2010 Feb 25.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk